<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04693715</url>
  </required_header>
  <id_info>
    <org_study_id>06.5.1.H1</org_study_id>
    <nct_id>NCT04693715</nct_id>
  </id_info>
  <brief_title>Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy</brief_title>
  <acronym>RESCUE</acronym>
  <official_title>RESCUE: A Randomized, Blinded, Placebo-controlled, Parallel Group Design to Determine the Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Revalesio Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Revalesio Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase II, randomized, blinded, placebo-controlled, parallel group study with patients&#xD;
      experiencing a large vessel occlusion acute ischemic stroke who are selected for endovascular&#xD;
      revascularization. Participants will be given a 48 h infusion of either 0.5 mL/kg/h RNS60 (up&#xD;
      to a maximum of 60 mL/h), 1 mL/kg/h RNS60 (up to a maximum of 120 mL/h), or 1 mL/kg/h (up to&#xD;
      a maximum of 120 mL/h) placebo (normal saline) starting within 30 minutes of consent after&#xD;
      confirmation of candidacy for endovascular thrombectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase II, randomized, blinded, placebo-controlled, parallel group design.&#xD;
      Participants experiencing a large vessel occlusion acute ischemic stroke who are selected for&#xD;
      endovascular revascularization will be given a 48 h infusion of either 0.5 mL/kg/h RNS60 (up&#xD;
      to a maximum of 60 mL/h), 1 mL/kg/h RNS60 (up to a maximum of 120 mL/h), or 1 mL/kg/h (up to&#xD;
      a maximum of 120 mL/h) placebo (normal saline) starting within 30 minutes of consent after&#xD;
      confirmation of candidacy for endovascular thrombectomy and prior to arterial closure.&#xD;
      Outcomes of the main trial will be evaluated throughout a 90 day observation period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2021</start_date>
  <completion_date type="Anticipated">July 7, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 7, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with serious adverse events</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality: proportion of participants alive</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean mRS score</measure>
    <time_frame>90 days</time_frame>
    <description>mRS = Modified Rankin Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in mortality rate</measure>
    <time_frame>90 days</time_frame>
    <description>Lower event rate on the Kaplan Meier survival curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean NIHSS score</measure>
    <time_frame>90 days</time_frame>
    <description>NIHSS = National Institutes of Health Stroke Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with a worsening of stroke</measure>
    <time_frame>90 days</time_frame>
    <description>Worsening of stroke defined as progression, or hemorrhagic transformation, of the index stroke as documented by medical imaging and that is (a) life-threatening requiring intervention and/or (b) results in increased disability as gauged by a ≥4 point increase from lowest NIHSS during hospitalization and/or (c) results in death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BI</measure>
    <time_frame>90 days</time_frame>
    <description>Mean Barthel Index (BI) at Day 90 relative to pre-stroke BI</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Infarct progression/regression</measure>
    <time_frame>90 days</time_frame>
    <description>Infarct size measured by MRI brain imaging</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life score</measure>
    <time_frame>90 days</time_frame>
    <description>Health-related quality of life as measured by the 5-level EuroQoL 5D index (EQ-5D-5L)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Stroke, Ischemic</condition>
  <arm_group>
    <arm_group_label>RNS60 0.5 mL/kg/h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RNS60 0.5 mL/kg/h infusion for 48h (up to a maximum of 60 mL/kg) starting within 30 min of randomization (but prior to arterial access closure)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RNS60 1 mL/kg/h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RNS60 1 mL/kg/h infusion for 48h (up to a maximum of 120 mL/kg) starting within 30 min of randomization (but prior to arterial access closure)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 1 mL/kg/h</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (normal saline) 1 mL/kg/h infusion for 48h (up to a maximum of 120 mL/kg) starting within 30 min of randomization (but prior to arterial access closure)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RNS60</intervention_name>
    <description>RNS60 injection solution</description>
    <arm_group_label>RNS60 0.5 mL/kg/h</arm_group_label>
    <arm_group_label>RNS60 1 mL/kg/h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo injection solution</description>
    <arm_group_label>Placebo 1 mL/kg/h</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Acute ischemic stroke (AIS) selected for emergency endovascular treatment.&#xD;
&#xD;
          2. Age 18 years or older.&#xD;
&#xD;
          3. Onset (last-known-well) time to randomization time within 24 hours.&#xD;
&#xD;
          4. Disabling stroke defined as a baseline National Institutes of Health Stroke Score&#xD;
             (NIHSS)&#xD;
&#xD;
               1. NIHSS &gt; 5 for internal carotid artery (ICA) and M1-middle cerebral artery (MCA)&#xD;
                  occlusion or&#xD;
&#xD;
               2. NIHSS &gt; 10 for M2-MCA occlusion.&#xD;
&#xD;
          5. Confirmed symptomatic intracranial occlusion at one or more of the following&#xD;
             locations: Intracranial carotid I/T/L, M1 or M2 segment MCA. Tandem extracranial&#xD;
             carotid and intracranial occlusions are permitted.&#xD;
&#xD;
          6. Pre-stroke (24 hours prior to stroke onset) independent functional status in&#xD;
             activities of daily living with modified Barthel Index (BI) ≥ 95. Patient must be&#xD;
             living without requiring nursing care.&#xD;
&#xD;
          7. Qualifying imaging performed less than 2 hours prior to randomization.&#xD;
&#xD;
          8. Consent process completed as per applicable laws and regulation and the IRB&#xD;
             requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of a large core of established infarction defined as ASPECTS 0-4.&#xD;
&#xD;
          2. Evidence of absence of collateral circulation on qualifying imaging (Collateral score&#xD;
             of 0 or 1).&#xD;
&#xD;
          3. Any evidence of intracranial hemorrhage or mass lesion on the qualifying imaging.&#xD;
&#xD;
          4. Planned use of an endovascular device not having approval or clearance by the relevant&#xD;
             regulatory authority.&#xD;
&#xD;
          5. Endovascular thrombectomy procedure is completed as defined by the presence of&#xD;
             arterial access closure.&#xD;
&#xD;
          6. Clinical history, past imaging or clinical judgment suggesting that the intracranial&#xD;
             occlusion is chronic or there is suspected intracranial dissection such that there is&#xD;
             a predicted lack of success with endovascular intervention.&#xD;
&#xD;
          7. Estimated or known weight &gt; 120 kg (264 lbs).&#xD;
&#xD;
          8. Known pregnant/lactating female.&#xD;
&#xD;
          9. Known prior myocardial infarction, or history of congestive heart failure (CHF).&#xD;
&#xD;
         10. Known renal impairment defined as requiring renal replacement therapy (hemo- or&#xD;
             peritoneal dialysis).&#xD;
&#xD;
         11. Inability to have MRI imaging (Non- MR compatible implants or any other foreseeable&#xD;
             reason, including claustrophobia)&#xD;
&#xD;
         12. Severe or fatal comorbid illness that will prevent improvement or follow up.&#xD;
&#xD;
         13. Inability to complete follow-up treatment to Day 90.&#xD;
&#xD;
         14. Participation in another clinical trial investigating a drug, medical device, or a&#xD;
             medical procedure in the 30 days preceding trial inclusion and throughout the duration&#xD;
             of the trial.&#xD;
&#xD;
         15. Seizure at onset.&#xD;
&#xD;
         16. Ischemic stroke within previous 30 days.&#xD;
&#xD;
         17. Baseline QTc &gt; 450 ms.&#xD;
&#xD;
         18. Any other symptom that in the investigator's opinion may complicate or preclude the&#xD;
             subject from participating in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wendy J Smith</last_name>
    <phone>401-444-4233</phone>
    <email>wsmith@lifespan.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Smith</last_name>
      <phone>401-444-4233</phone>
      <email>wsmith@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Ryan McTaggart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 31, 2020</study_first_submitted>
  <study_first_submitted_qc>December 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endovascular Thrombectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>RNS60</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

